The Business of Healthcare Innovation
Lawton Robert Burns
Cambridge University Press, Jul 26, 2012 - Business & Economics
The Business of Healthcare Innovation is a wide-ranging analysis of business trends in the manufacturing segment of the healthcare industry. It provides a thorough overview and introduction to the innovative sectors fueling improvements in healthcare: pharmaceuticals, biotechnology, platform technology, medical devices and information technology. For each sector, the book examines the basis and trends in scientific innovation, the business and revenue models pursued to commercialize that innovation, the regulatory constraints within which each sector must operate and the growing issues posed by more activist payers and consumers. Specific topics include market structure and competition, the economics and rationale of product development, pricing, sales and marketing, contract negotiations with buyers, alliances versus mergers, business strategies and prospects for growth. Written by professors of the Wharton School and industry executives, the book shows why healthcare sectors are such an important source of growth in any nation's economy.
What people are saying - Write a review
We haven't found any reviews in the usual places.
rebooted and reinvigorated 32
Pharmaceutical strategy and the evolving role of merger and acquisition 116
Other editions - View all
Accessed Feb Accessed Jan Accessed Sept acquisition Amgen antibodies approval AstraZeneca Available beneﬁts billion biologics Biotech biotechnology companies biotechnology ﬁrms biotechnology sector Burrill and Company business models challenges clinical trials company’s convergence cost CPOE created deals decade deﬁbrillators disease drug development drug discovery economic Ernst and Young ﬁeld Figure ﬁnancial ﬁnancing ﬁnd ﬁrst ﬁve funding gene gene therapy Genentech genomics global growth Health healthcare hospital human Ibid impact implants increased industry innovation integration investment investors large pharmaceutical manufacturing medical device medical products medicine Medtronic Merck merger molecules monoclonal antibodies NMEs Novartis organizations outsourcing patients payers percent Pfizer Pharma pharmaceutical companies pharmaceutical ﬁrms pharmaceutical sector phase physicians pipeline platform potential proﬁt programs protein proteomics regulatory revenues Sanofi-Aventis Sciences scientiﬁc signiﬁcant Source speciﬁc spending stents strategy success target technological convergence therapeutic therapy tion value chain venture capital Vivo